NASDAQ: SABS - SAB Biotherapeutics, Inc.

Lønnsomhet i seks måneder: -40.37%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan SAB Biotherapeutics, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.

flere detaljer
The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2021-02-09
ISIN US78397T1034
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.sabbiotherapeutics.com
Цена ао 1.63
Prisendring per dag: -1.23% (1.63)
Prisendring per uke: -0.6173% (1.62)
Prisendring per måned: -5.85% (1.71)
Prisendring over 3 måneder: -60.54% (4.08)
Prisendring over seks måneder: -40.37% (2.7)
Prisendring per år: -70.83% (5.52)
Prisendring over 3 år: -24.77% (2.14)
Prisendring over 5 år: 0% (1.61)
Prisendring over 10 år: 0% (1.61)
Prisendring siden begynnelsen av året: -62.38% (4.28)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 1.75 8
P/BV 0.0684 10
P/E 0 0
EV/EBITDA 1.36 10
Total: 6

Effektivitet

Navn Betydning Karakter
ROA, % -50.27 0
ROE, % -73.64 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.1721 10
Total: 9.6

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % -34.15 0
Lønnsomhet Ebitda, % 365.04 10
Lønnsomhet EPS, % 3428.04 10
Total: 8
Flere detaljer

Institusjoner Volum Dele, %
Marshall Wace LLP 4585282 49.7
RA Capital Management, L.P. 2374081 25.73
COMMODORE CAPITAL LP 1831746 19.86
RTW Investments LP 917828 9.95
BVF Inc. 917828 9.95
Sessa Capital IM, L.P. 458457 4.97
Vanguard Group Inc 99614 1.08
First Premier Bank 80754 0.88
Pathstone Holdings, LLC 50651 0.55
Geode Capital Management, LLC 35636 0.39

ETFDele, %Lønnsomhet for året, %Utbytte, %
iShares Micro-Cap ETF 0.00541 17.09 1.54048
0.0117.091.54



Veileder Stillingstittel Betaling Fødselsår
Mr. Samuel J. Reich CEO & Executive Chairman 363.2k 1975 (50 år)
Dr. Eddie Joe Sullivan Ph.D. Co-Founder, President & Director 402.56k 1966 (59 år)
Ms. Christine E. Hamilton M.B.A. Co-Founder & Independent Director 25k 1956 (69 år)
Dr. Alexandra Kropotova M.B.A., M.D. Executive VP & Chief Medical Officer 774.45k 1973 (52 år)
Dr. Edward D. Hamilton D.V.M. Co-Founder & Board Observer N/A
Dr. Christoph Bausch M.B.A., Ph.D. Executive VP & COO 443.2k 1971 (54 år)
Dr. Carlos N. Carillo Ph.D. Senior Vice President of Regulatory Affairs N/A
Mr. Mark W. Conley Interim Chief Financial Officer

Adresse: United States, Sioux Falls. SD, 2100 East 54th Street North - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.sabbiotherapeutics.com